Preservative free artificial tear
PreclinicalSmall molecule
Preservative free artificial tear is one of 51 small molecule programs targeting Cataract. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Eylea
RegeneronApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Cipro
BayerApproved
Voltaren
NovartisApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details